scholarly journals OC08.04: Oral administration of norethisterone acetate in women with adenomyosis: effects on ultrasound features and clinical symptoms

2019 ◽  
Vol 54 (S1) ◽  
pp. 20-20
Author(s):  
L. Lazzeri ◽  
C. Exacoustos ◽  
G. Monti ◽  
G. Centini ◽  
F. Conway ◽  
...  
Keyword(s):  
Oral Administration ◽  
Clinical Symptoms ◽  
Norethisterone Acetate ◽  
Ultrasound Features

scholarly journals BLOOD CHANGES AND CLINICAL SYMPTOMS FOLLOWING ORAL ADMINISTRATION OF PHOSPHATES

1924 ◽  
Vol 60 (2) ◽  
pp. 311-326
Author(s):  
Harald A. Salvesen ◽  
A.Baird Hastings ◽  
J.F. McIntosh
Keyword(s):  
Oral Administration ◽  
Clinical Symptoms

Tularemia

2016 ◽  
Author(s):  
Alida Gertz
Keyword(s):  
Health Care ◽  
Antibiotic Resistance ◽  
Oral Administration ◽  
Supportive Care ◽  
Health Care System ◽  
Francisella Tularensis ◽  
Small Mammals ◽  
Clinical Symptoms ◽  
Gram Negative ◽  
Route Of Transmission

Tularemia, caused by the gram-negative coccobacillus Francisella tularensis, is an extremely infectious bacterial zoonosis. Symptoms depend on site of exposure; they can be nonspecific and may include fever, lymphadenopathy, ulcer or papule, and nausea/vomiting. Natural transmission occurs via small mammals, such as rabbits, or arthropod bites. IV or IM antibiotics are preferred over oral forms. Supportive care is also critical; some patients may require respiratory support. If used as a biological weapon, aerosolized F. tularensis would be the most likely route of transmission. Clinical symptoms would include those of pneumonic tularemia. In the event of a bioterrorist attack, oral administration antibiotics can be used, as the health care system may not be able to accommodate intravenous or intramuscular treatment. Antibiotic resistance should also be considered if patients deteriorate despite use of recommended antibiotics.

Long-term oral administration of transgenic rice containing cedar pollen T-cell epitopes potentially improves medication- and allergy-related quality-of-life scores

2021 ◽  
Vol 42 (4) ◽  
pp. 293-300 ◽  
Author(s):  
Tomonori Endo ◽  
Daiya Asaka ◽  
Tsuguhisa Nakayama ◽  
Shota Saito ◽  
Hiroki Kodama ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cell Proliferation ◽  
T Cell ◽  
Oral Administration ◽  
Transgenic Rice ◽  
Clinical Symptoms ◽  
T Cell Proliferation ◽  
T Cell Epitopes ◽  
Cry J 2

Background: We previously developed a transgenic rice that contains seven linked human predominant T-cell epitopes (7Crp) derived from Japanese cedar (JC) pollen allergens Cry j 1 and Cry j 2. Oral administration of 80 g of transgenic rice for 20 weeks suppressed allergen-specific T-cell proliferation in participants with JC pollinosis, but their clinical symptoms did not improve. Objective: We examined the clinical efficacy of low-dose (5 g and 20 g) intake of the transgenic rice administered for two successive seasons. Methods: In this randomized, double-blind, placebo controlled study, transgenic rice seeds (5 g or 20 g) were orally administered to the participants for 24 weeks in each of two successive JC pollen seasons. We analyzed T-cell proliferation and cytokine expression, and monitored symptom and medication scores during the pollen season. Quality of life (QOL) was evaluated by using the Japanese Allergic Rhinitis Quality of Life Standard Questionnaire (JRQLQ). Results: Specific T-cell proliferation after stimulation with 7Crp, Cry j 1, and Cry j 2 was significantly suppressed in the second JC pollen season. No significant differences were found among the three groups (5 g, 20 g, and placebo) with regard to clinical symptoms or medication scores in the first season. However, the medication scores and face scale for overall condition of JRQLQ improved in the 5-g transgenic rice group in the second season, although careful re-examination with a large sample size is necessary to confirm the results. Conclusion: Low-dose oral administration of transgenic rice that contains 7Crp significantly reduced allergen-specific T-cell responses and improved medication scores during the second season of administration. Thus, oral intake of the transgenic rice has the potential to induce immune tolerance to JC pollen allergens when administered for at least two successive seasons.

scholarly journals Withania frutescens. L Extract: Phytochemical Characterization and Acute and Repeated Dose 28-Day Oral Toxicity Studies in Mice

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Abdelfattah EL Moussaoui ◽  
Mohammed Bourhia ◽  
Fatima Zahra Jawhari ◽  
Imane Es-safi ◽  
Syed Saeed Ali ◽  
...  
Keyword(s):  
Acute Toxicity ◽  
Oral Administration ◽  
Biochemical Parameters ◽  
Clinical Symptoms ◽  
Toxicity Study ◽  
Control Group ◽  
Oral Toxicity ◽  
Traditional Use ◽  
Subacute Toxicity ◽  
Acute Toxicity Study

Background. Withania frutescens. L (W. frutescens) is a perennial woody medicinal plant belonging to family Solanaceae largely used by the indigenous population to Morocco for the treatment of disease. Objective. The purpose of this study was to investigate the chemical composition, acute, and subacute toxicity of W. frutescens extract in mice. Materials and Methods. The phytochemical composition of W. frutescens extract was determined using a gas chromatograph (GC/MS). Acute toxicity study was carried out in mice through oral administration of single doses 500 mg/kg, 1000 mg/kg, and 2000 mg/kg for 14 days. Subacute toxicity was performed with oral administration of repeated doses 500 and 2000 mg/kg/day for 28 days. Biochemical parameters (alanine aminotransferase, aspartate aminotransferase, urea, and creatinine), as well as histopathological changes potentially occurred in organs, (liver, kidney, and spleen) were evaluated. Results. The results of chromatographic analysis showed the richness of W. frutescens extract in interesting phytochemical compounds majorly constituted of bicyclo[3.1.1]heptane, 6,6-dimethyl-2-methylene-(C10H16). Regarding acute toxicity study, the results showed no clinical symptoms occurred in treated mice compared to the control group and no histological changes detected in analyzed organs of treated mice with dose put to 2000 mg/kg nor adverse effect on biochemical parameters. Conclusion. The outcome of this work showed no toxic effect of W. frutescens in mice up to dose 2000 mg/kg bodyweight. Therefore, this study could scientifically validate further traditional use with safety in the range of tested doses.

scholarly journals Toxicokinetics of Hydrolyzed Fumonisin B1 after Single Oral or Intravenous Bolus to Broiler Chickens Fed a Control or a Fumonisins-Contaminated Diet

Toxins ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 413 ◽  
Author(s):  
Gunther Antonissen ◽  
Siegrid De Baere ◽  
Barbara Novak ◽  
Dian Schatzmayr ◽  
Danica den Hollander ◽  
...  
Keyword(s):  
Oral Administration ◽  
Broiler Chickens ◽  
Clinical Symptoms ◽  
Control Diet ◽  
Plasma Concentrations ◽  
Fumonisin B1 ◽  
Ultra Performance Liquid Chromatography ◽  
Limit Of Quantification ◽  
Liquid Chromatography Tandem Mass ◽  
Hydrolyzed Fumonisin

The toxicokinetics (TK) of hydrolyzed fumonisin B1 (HFB1) were evaluated in 16 broiler chickens after being fed either a control or a fumonisins-contaminated diet (10.8 mg fumonisin B1, 3.3 mg B2 and 1.5 mg B3/kg feed) for two weeks, followed by a single oral (PO) or intravenous (IV) dose of 1.25 mg/kg bodyweight (BW) of HFB1. Fumonisin B1 (FB1), its partially hydrolyzed metabolites pHFB1a and pHFB1b, and fully hydrolyzed metabolite HFB1, were determined in chicken plasma using a validated ultra-performance liquid chromatography–tandem mass spectrometry method. None of the broiler chicken showed clinical symptoms of fumonisins (FBs) or HFB1 toxicity during the trial, nor was an aberration in body weight observed between the animals fed the FBs-contaminated diet and those fed the control diet. HFB1 was shown to follow a two-compartmental pharmacokinetic model with first order elimination in broiler chickens after IV administration. Toxicokinetic parameters of HFB1 demonstrated a total body clearance of 16.39 L/kg·h and an intercompartmental flow of 8.34 L/kg·h. Low levels of FB1 and traces of pHFB1b were found in plasma of chickens fed the FBs-contaminated diet. Due to plasma concentrations being under the limit of quantification (LOQ) after oral administration of HFB1, no toxicokinetic modelling could be performed in broiler chickens after oral administration of HFB1. Moreover, no phase II metabolites, nor N-acyl-metabolites of HFB1 could be detected in this study.

scholarly journals Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report

2020 ◽  
Vol 2020 ◽  
pp. 1-7 ◽  
Author(s):  
Shiro Mawatari ◽  
Shinji Ohara ◽  
Yoshihide Taniwaki ◽  
Yoshio Tsuboi ◽  
Toru Maruyama ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Oral Administration ◽  
Peripheral Blood ◽  
Sleep Problems ◽  
Clinical Symptoms ◽  
Blood Levels ◽  
Nonmotor Symptoms ◽  
Ether Phospholipids ◽  
Normal Controls

Introduction. Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease (AD). With the ageing of population, the frequency of PD is expected to increase dramatically in the coming decades. L-DOPA (1,3,4-dihydroxyalanine) is the most effective drug in the symptomatic treatment of PD. Nonmotor symptoms in PD include sleep problems, depression, and dementia, which are not adequately controlled with dopaminergic therapy. Here, we report the efficacy of oral administration of scallop-derived ether phospholipids to some nonmotor symptoms of PD. Methods. Ten (10) patients received oral administration of 1 mg/day of purified ether phospholipids derived from scallop for 24 weeks. Clinical symptoms and blood tests were checked at 0, 4, 12, 24, and 28 weeks. The blood levels of plasmalogens in patients with PD were compared with those of 39 age-matched normal controls. Results. Initial levels of plasma ethanolamine ether phospholipids in PD and ethanolamine plasmalogen of erythrocyte from PD were lower than those of age-matched normal controls. Oral administration of 1 mg/day of the purified ether phospholipids increased plasma ether phospholipids in PD and increased the relative composition of ether phospholipids of erythrocyte membrane in PD. The levels of ether phospholipids in peripheral blood reached to almost normal levels after 24 weeks. Furthermore, some clinical symptoms of PD improved concomitantly. Conclusion. 1 mg/day of oral administration of purified ether phospholipids derived from scallop can increase ether phospholipids in peripheral blood and concomitantly improve some clinical symptoms of PD.

scholarly journals Oral administration ofLactobacillus brevisKB290 to mice alleviates clinical symptoms following influenza virus infection

2013 ◽  
Vol 58 (1) ◽  
pp. 87-93 ◽  
Author(s):  
N. Waki ◽  
N. Yajima ◽  
H. Suganuma ◽  
B.M. Buddle ◽  
D. Luo ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Infection ◽  
Oral Administration ◽  
Clinical Symptoms ◽  
Influenza Virus Infection
Sign in / Sign up

Export Citation Format

Share Document